Ian joined Karyopharm in July 2018 and is responsible for leading the company’s corporate communications activities, including corporate visibility, financial communications, and media and investor relations.
Prior to joining Karyopharm, Ian held several roles with increasing responsibility at Shire plc, culminating in his role as Vice President and Head of Global Investor Relations. In addition, Ian previously served as Shire’s Head of Commercial Assessment and played a critical role in Shire’s corporate acquisition strategy between 2012-2016 which resulted in acquisitions totaling more than $40B, including ViroPharma, Dyax, and Baxalta.
Before joining Shire, Ian served as Senior Director for Global Marketing, Emerging Oncology Brands at MedImmune, an AstraZeneca company. In this role, Ian served as MedImmune’s commercial lead for clinical and preclinical programs across 20+ cancer indications in both solid tumors and hematological malignancies. Prior to his time at MedImmune, Ian held positions at Johnson & Johnson’s Centocor division as well as at Pharmacia (now part of Pfizer) in a variety of sales and marketing roles, including field reimbursement support for Pharmacia’s cancer franchise.
Ian received a Bachelor of Science degree in biology from Emory University and an MBA from Rutgers Business School with a concentration in pharmaceutical management.